TY - JOUR AU - Okba, Nisreen M.A. AU - Müller, Marcel AU - Li, Wentao AU - Wang, Chunyan AU - GeurtsvanKessel, Corine AU - Corman, Victor AU - Lamers, Mart AU - Sikkema, Reina AU - de Bruin, Erwin AU - Chandler, Felicity AU - Yazdanpanah, Yazdan AU - Le Hingrat, Quentin AU - Descamps, Diane AU - Houhou-Fidouh, Nadhira AU - Reusken, Chantal B.E.M. AU - Bosch, Berend-Jan AU - Drosten, Christian AU - Koopmans, Marion P.G. AU - Haagmans, Bart T1 - Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients T2 - Emerging Infectious Disease journal PY - 2020 VL - 26 IS - 7 SP - 1478 SN - 1080-6059 AB - A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein–specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2–infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2–specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies. KW - Severe acute respiratory syndrome coronavirus 2 KW - SARS-CoV-2 KW - coronavirus KW - viruses KW - 2019 novel coronavirus disease KW - COVID-19 KW - antibodies KW - serologic analysis KW - spike KW - receptor-binding domain KW - RBD KW - nucleocapsid KW - neutralization KW - ELISA KW - respiratory diseases KW - xoonoses KW - human coronavirus KW - HCoV KW - coronavirus disease 2019 KW - spike protein KW - nucleocapsid protein KW - respiratory infections KW - zoonoses DO - 10.3201/eid2607.200841 UR - https://wwwnc.cdc.gov/eid/article/26/7/20-0841_article ER - End of Reference